Imagine if health and trade ministers would meet in one room this week
A earlier version of this commentary was published on 28 November 2021 by Barron's.
This is a time of missed opportunities. This week, trade ministers...
The elephant in the room at the WHO Executive Board
The World Health Organization (WHO) Director-General, Dr Tedros Adhanom Ghebreyesus spoke harshly about the lack of Covid-19 vaccines in developing countries at the opening of...
Access to medicines amendment of the WTO TRIPS Agreement. Hype or hope?
On 30 January 2017 the World Trade Organization (WTO) announced the first ever amendment to the TRIPS Agreement under the headline WTO members welcome...
Pharmaceutical Accountability Foundation meets AbbVie in court, looking to advance its pricing case
“The value of a human life is infinite, but unfortunately our healthcare budget is not,” said former Dutch Health Minister Bruno Bruins, quoted by...
Medicines price transparency: Ground still left to cover
Parts of this blog were previously published in the Lancet Regional Health Europe
Secret medicines prices are hotly debated as European health systems struggle to...
Dolutegravir Patent Licences Can Provide Access To All
This year the World Health Organization (WHO) added dolutegravir, an antiretroviral medicine for the treatment of HIV infection, to its Model List of Essential...
Wrapping up 2024: Noteworthy events in medicines law and policy around the globe
Welcome to Medicines Law & Policy’s end of the year blog, our highly biased annual overview of memorable medicines law and policy events.
January
At the...
CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests
On 25th July 2018, the Court of Justice of the European Union (CJEU) rendered its preliminary ruling on the interpretation of Article 3(a) of Regulation...
The European Commission’s compulsory licensing proposals are sensible but do not go far enough
An earlier version of this comment was published in Barron's on 21 July 2023. A Spanish translation of it is also available from El...
Pharmaceutical Accountability Foundation is taking AbbVie to court over excessive pricing of Humira –...
On 21 February, the Dutch Pharmaceutical Accountability Foundation (PAF) took the bold step to take AbbVie to court, claiming the company’s pricing policy had...